Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | BSH 2017 lymphoma highlights: looking at synergies between immuno-oncology agents

Graham Collins • 27 Mar 2017
BSH 2017
Hodgkin Lymphoma Non-Hodgkin Lymphoma Antibodies

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil of Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses his highlights from the Free Lymphoma/CLL Communications session held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Dr Collins highlights a presentation on preclinical research looking at potential synergies between immune-oncology agents; it showed the potential for a combination between anti-CD20 and anti-CD27 antibodies in lymphoma.

More from Graham Collins

Future frontline Hodgkin lymphoma strategies aim to reduce treatment toxicity
1:43
Future frontline Hodgkin lymphoma strategies aim to reduce treatment toxicity
Graham Collins • 13 Jun 2026
AVENUE final analysis supports frontline avelumab in Hodgkin lymphoma
1:27
AVENUE final analysis supports frontline avelumab in Hodgkin lymphoma
Graham Collins • 13 Jun 2026
BrECADD vs Nivo-AVD in advanced Hodgkin lymphoma: selecting the right patients
2:09
BrECADD vs Nivo-AVD in advanced Hodgkin lymphoma: selecting the right patients
Graham Collins • 13 Jun 2026
Current treatment approaches for relapsed Hodgkin lymphoma & challenges that remain
3:22
Current treatment approaches for relapsed Hodgkin lymphoma & challenges that remain
Graham Collins • 28 May 2025

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals